报价延迟最少15分钟:2025/08/25 04:51 EDT
盘前时段
|
||||
|
-- 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
31.44
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-14.90/4.94
|
|
企业价值
3.05B
|
| 资产负债 |
|
每股账面净值
45.10
|
| 现金流量 |
|
现金流量率
0.11
|
| 损益表 |
|
收益
2.11B
|
|
每股收益
29.06
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/08/25 04:51 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S. |
